Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  H. Möller,et al.  Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) Part 1: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part I: Acute and continuation treatment of major depressive disorder , 2009 .

[3]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[4]  J. Drazen,et al.  Full disclosure and the funding of biomedical research. , 2008, The New England journal of medicine.

[5]  M. Thase,et al.  Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs , 2008, Biological Psychiatry.

[6]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[7]  David Rindskopf,et al.  Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[8]  R. Poole,et al.  Selective publication of antidepressant trials. , 2008, The New England journal of medicine.

[9]  R. Shelton,et al.  Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents , 2007, Biological Psychiatry.

[10]  I. Kirsch,et al.  Clinical trials and the response rate illusion. , 2007, Contemporary clinical trials.

[11]  I. Florea,et al.  A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder , 2007, Current medical research and opinion.

[12]  M. Thase,et al.  A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. , 2007, Journal of psychiatric research.

[13]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[14]  A. Cipriani,et al.  What is a risk ratio? , 2007, Epidemiologia e Psichiatria Sociale.

[15]  E. Armstrong,et al.  Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial* , 2007, Current medical research and opinion.

[16]  A. Nierenberg,et al.  Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study* , 2007, Current medical research and opinion.

[17]  Hans-Jürgen Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[18]  G. Alexopoulos,et al.  Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder , 2007, Clinical drug investigation.

[19]  C. François,et al.  Can discrete event simulation be of use in modelling major depression? , 2006, Cost effectiveness and resource allocation : C/E.

[20]  R. Shelton,et al.  A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. , 2006, The Journal of clinical psychiatry.

[21]  E. Demir,et al.  Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial , 2006, Advances in therapy.

[22]  N. Freemantle,et al.  Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. , 2006, Archives of general psychiatry.

[23]  B. Haight,et al.  A Double-blind Comparison Between Bupropion XL and Venlafaxine XR: Sexual Functioning, Antidepressant Efficacy, and Tolerability , 2006, Journal of clinical psychopharmacology.

[24]  M. Flores-Ramos,et al.  Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. , 2006, Journal of affective disorders.

[25]  M. Detke,et al.  Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial , 2006, European Psychiatry.

[26]  T. Kinoshita,et al.  Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients , 2006, Neuropsychobiology.

[27]  M. Hotopf,et al.  Are all antidepressants really the same? The case of fluoxetine: a systematic review. , 2006, The Journal of clinical psychiatry.

[28]  M. Sarchiapone,et al.  A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients , 2006, Current medical research and opinion.

[29]  N. Richard,et al.  Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. , 2006, The Journal of clinical psychiatry.

[30]  I. Hindmarch,et al.  A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder , 2006, International clinical psychopharmacology.

[31]  A. Schatzberg,et al.  A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[32]  O. Bodlund,et al.  Efficacy and Tolerability of Reboxetine Compared with Citalopram: A Double-blind Study in Patients with Major Depressive Disorder , 2006, Journal of clinical psychopharmacology.

[33]  A. Szegedi,et al.  Mirtazapine Orally Disintegrating Tablets Versus Venlafaxine Extended Release: A Double-blind, Randomized Multicenter Trial Comparing the Onset of Antidepressant Response in Patients With Major Depressive Disorder , 2006, Journal of clinical psychopharmacology.

[34]  T. Burt,et al.  Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. , 2005, The Journal of clinical psychiatry.

[35]  A. Serretti,et al.  Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression: A Double-blind, Randomized Trial , 2005 .

[36]  S. Kasper,et al.  Escitalopram in the treatment of depressed elderly patients. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[37]  L. Colonna,et al.  A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder* , 2005, Current medical research and opinion.

[38]  K. Lohr,et al.  Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder , 2005, Annals of Internal Medicine.

[39]  B. Kee,et al.  Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression , 2005, Current medical research and opinion.

[40]  N. Moore,et al.  Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder , 2005, International clinical psychopharmacology.

[41]  S. Akhondzadeh,et al.  Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double‐blind, randomized trial , 2005, Journal of clinical pharmacy and therapeutics.

[42]  T. Furukawa,et al.  Imputing response rates from means and standard deviations in meta-analyses , 2005, International clinical psychopharmacology.

[43]  M. Ansseau,et al.  Controlled comparison of milnacipran and fluoxetine in major depression , 1994, Psychopharmacology.

[44]  M. Versiani,et al.  Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients , 2005, CNS drugs.

[45]  A. Sarandol,et al.  [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. , 2005, Turk psikiyatri dergisi = Turkish journal of psychiatry.

[46]  Nice.  Depression: management of depression in primary and secondary care , 2005 .

[47]  E. Weiller,et al.  A comparative study of milnacipran and paroxetine in outpatients with major depression. , 2004, Journal of affective disorders.

[48]  K. Behnke,et al.  Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopram , 2004, International journal of geriatric psychiatry.

[49]  M. Detke,et al.  Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial , 2004, European Neuropsychopharmacology.

[50]  R. Bielski,et al.  A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. , 2004, The Journal of clinical psychiatry.

[51]  S. Montgomery,et al.  A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder , 2004, Neuropsychobiology.

[52]  M. Hotopf,et al.  "Wish Bias" in Antidepressant Drug Trials? , 2004, Journal of clinical psychopharmacology.

[53]  S. Khanzode,et al.  Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors , 2003, Redox report : communications in free radical research.

[54]  N. DeMartinis,et al.  Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. , 2003, The Journal of clinical psychiatry.

[55]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[56]  I. Katz,et al.  Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. , 2003, The Journal of clinical psychiatry.

[57]  K. Behnke,et al.  Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study , 2003, Journal of clinical psychopharmacology.

[58]  S. Tsai,et al.  A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. , 2003, The Journal of clinical psychiatry.

[59]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. , 2003 .

[60]  U. Lepola,et al.  Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care , 2003, International clinical psychopharmacology.

[61]  J. Daléry,et al.  Fluvoxamine versus fluoxetine in major depressive episode: a double‐blind randomised comparison , 2003, Human psychopharmacology.

[62]  J. Zajecka,et al.  Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder , 2003, International clinical psychopharmacology.

[63]  A. Wade,et al.  A randomized, double‐blind, 24‐week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care , 2003, International clinical psychopharmacology.

[64]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[65]  Milnacipran versus Sertraline in Major Depressive Disorder : A Double-Blind Randomized Comparative Study on the Treatment Effect and β-Adrenergic Receptor Responsiveness , 2003 .

[66]  M. Posternak,et al.  Symptom Severity and Exclusion From Antidepressant Efficacy Trials , 2002, Journal of clinical psychopharmacology.

[67]  A. Schatzberg,et al.  Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[68]  J. Rybakowski,et al.  Reboxetine, a New Noradrenaline Selective Antidepressant, Is at Least as Effective as Fluoxetine in the Treatment of Depression , 2002, Journal of clinical psychopharmacology.

[69]  Peter Jüni,et al.  Quality of reporting of randomized trials as a measure of methodologic quality. , 2002, JAMA.

[70]  P. Linkowski,et al.  Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. , 2002, The international journal of neuropsychopharmacology.

[71]  M. Detke,et al.  Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine , 2002, European Neuropsychopharmacology.

[72]  N. Freemantle,et al.  Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. , 2002, The British journal of psychiatry : the journal of mental science.

[73]  D. Kupfer,et al.  Placebo in clinical trials for depression: complexity and necessity. , 2002, JAMA.

[74]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[75]  M. Fava,et al.  Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia , 2002, Journal of clinical psychopharmacology.

[76]  W. Burke,et al.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. , 2002, The Journal of clinical psychiatry.

[77]  Craig Mallinckrodt,et al.  Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. , 2002, The Journal of clinical psychiatry.

[78]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[79]  J. Guelfi,et al.  Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features , 2001, Journal of clinical psychopharmacology.

[80]  N. Richard,et al.  A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. , 2001, Clinical therapeutics.

[81]  G. Clerc.  Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine , 2001, International clinical psychopharmacology.

[82]  Jonathan A C Sterne,et al.  Sifting the evidence—what's wrong with significance tests? , 2001, BMJ : British Medical Journal.

[83]  Venlafaxine vs imipramine, sertraline in treating depression , 2001 .

[84]  L. Ekselius,et al.  Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. , 2000, Journal of clinical psychopharmacology.

[85]  S. Stahl.  Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline , 2000, Biological Psychiatry.

[86]  A. Szegedi,et al.  Mirtazapine compared with paroxetine in major depression. , 2000, The Journal of clinical psychiatry.

[87]  R. Donahue,et al.  Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. , 2000, The Journal of clinical psychiatry.

[88]  K. Krishnan,et al.  A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. , 2000, The Journal of clinical psychiatry.

[89]  M. Fava,et al.  Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. , 2000, Journal of affective disorders.

[90]  K. Behnke,et al.  Randomized, Double-Blind Comparison of Venlafaxine and Sertraline in Outpatients With Major Depressive Disorder , 2000 .

[91]  M. Guazzelli,et al.  Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia , 2000, International clinical psychopharmacology.

[92]  M. Frye,et al.  Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. , 2000, The Journal of clinical psychiatry.

[93]  A. Feiger,et al.  A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. , 1999, Journal of affective disorders.

[94]  K. Behnke,et al.  Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. , 1999, International clinical psychopharmacology.

[95]  R. Donahue,et al.  Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment , 1999, European Neuropsychopharmacology.

[96]  R. Remick,et al.  A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. , 1999, Journal of affective disorders.

[97]  R. Donahue,et al.  A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. , 1999, Clinical therapeutics.

[98]  H. Möller,et al.  Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. , 1999, International clinical psychopharmacology.

[99]  P. Boyer,et al.  A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients , 1999, European Psychiatry.

[100]  A. Ravindran,et al.  Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. , 1999, The Journal of clinical psychiatry.

[101]  J. Amsterdam,et al.  A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression , 1998 .

[102]  L. Gamito,et al.  Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression , 1998, European Neuropsychopharmacology.

[103]  Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression , 1998, European Neuropsychopharmacology.

[104]  J. C. E. Silva.  Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. , 1998 .

[105]  D. Wheatley,et al.  Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. , 1998, Journal of Clinical Psychiatry.

[106]  J. Guelfi,et al.  A double‐blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients , 1998, International clinical psychopharmacology.

[107]  A. Ontiveros,et al.  A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. , 1998, Clinical therapeutics.

[108]  G. Guyatt,et al.  Interpreting treatment effects in randomised trials , 1998, BMJ.

[109]  J. Amsterdam,et al.  A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. , 1998, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[110]  Á. N. Chonchubhair.  Selective serotonin reuptake inhibitors. , 1998, Anaesthesia.

[111]  J. A. Costa e Silva.  Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. , 1998, The Journal of clinical psychiatry.

[112]  R. Segraves,et al.  Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. , 1997, The Journal of clinical psychiatry.

[113]  L. Knorring,et al.  P.1.040 A double-blind study comparing sertraline and citalopram in patients with major depression treated in general practice , 1997, European Neuropsychopharmacology.

[114]  J. Casoy,et al.  P.1.083 A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practise , 1997, European Neuropsychopharmacology.

[115]  T. Bougerol,et al.  Citalopram and Fluoxetine in Major Depression , 1997 .

[116]  A. Feiger,et al.  A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. , 1997, The Journal of clinical psychiatry.

[117]  S. Montgomery,et al.  Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability , 1997, International clinical psychopharmacology.

[118]  E. Smeraldi,et al.  Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. , 1996, The American journal of psychiatry.

[119]  L. Fabre,et al.  A comparison of fluvoxamine and fluoxetine in the treatment of major depression. , 1996, Journal of clinical psychopharmacology.

[120]  C. Hoogduin,et al.  Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double‐blind, multicentre study , 1996 .

[121]  T. Bougerol,et al.  Citalopram versus fluoxetine: a double‐blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice , 1996, International clinical psychopharmacology.

[122]  Alain Martin,et al.  A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[123]  C. Hoogduin,et al.  Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. , 1996, International clinical psychopharmacology.

[124]  P. Cosyns,et al.  A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression , 1995 .

[125]  J. M. Mullin,et al.  A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. , 1995, The Journal of clinical psychiatry.

[126]  J. Feighner,et al.  Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients , 1995 .

[127]  M. Ansseau,et al.  Controlled comparison of paroxetine and fluvoxamine in major depression , 1994 .

[128]  G. Clerc,et al.  A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia , 1994 .

[129]  G. Clerc,et al.  A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. , 1994, International clinical psychopharmacology.

[130]  J. Tignol.  A Double‐Blind, Randomized, Fluoxetine‐Controlled, Multicenter Study of Paroxetine in the Treatment of Depression , 1993, Journal of clinical psychopharmacology.

[131]  C. Mertens,et al.  A double‐blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients , 1993, Acta psychiatrica Scandinavica.

[132]  C. Faravelli,et al.  Double‐blind study of the efficacy and safety of sertraline versus fluoxetine in major depression , 1993, International clinical psychopharmacology.

[133]  J. Feighner,et al.  Double-blind comparison of bupropion and fluoxetine in depressed outpatients. , 1991, The Journal of clinical psychiatry.

[134]  World federation of societies of biological psychiatry , 1990, Biological Psychiatry.

[135]  C Mertens,et al.  Paroxetine in the treatment of depression , 1988, Acta psychiatrica Scandinavica.

[136]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.